Search for: "AMGEN, INC" Results 81 - 100 of 702
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Dec 2022, 7:59 am by Dennis Crouch
Full Scope Enabling Written Description: The court has granted only one petition, Amgen Inc., v. [read post]
7 Dec 2022, 8:00 am by Linda C. Severin
  While there, she prosecuted many notable FCA cases including several qui tam cases against National Medicare Care, Inc. [read post]
27 Nov 2022, 8:10 pm by Patent Docs
Paul Berghoff of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Stephanie Donahue of Sanofi; Henry Hadad of Bristol-Meyers Squibb Co.; and Stuart Watt of Amgen, Inc. that will discuss the issues and arguments concerning the current state of enablement and written description law and where the law may be headed. [read post]
5 Oct 2022, 6:30 am
Posted by Laura Harder, Cleary Gottlieb Steen & Hamilton LLP, on Wednesday, October 5, 2022 Editor's Note: Laura Harder is an Associate at Cleary Gottlieb Steen & Hamilton LLP. [read post]
26 Sep 2022, 4:49 am by Dennis Crouch
Full Scope Enablement in Amgen Inc. v. [read post]
18 Aug 2022, 4:43 am by Melissa Tremblay
  Suzanne prosecuted many notable FCA cases in the government, including several qui tam cases against National Medicare Care, Inc. [read post]
1 Jul 2022, 10:02 am by Dennis Crouch
The current most-likely big case is Amgen Inc., et al. v. [read post]
16 May 2022, 12:16 pm by Dennis Crouch
Qualcomm Incorporated (licensee appellate standing) and Amgen Inc. v. [read post]